GlassScriptPhysician profile
Michael James Gilhooley
NPI 1093751034
$8,799.36
in general payments reported to CMS, 2019-2025
47 companies · $913 in 2025
The $913 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,141 · 2020: $535 · 2021: $1,608 · 2022: $1,769 · 2023: $1,780 · 2024: $1,053 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,746.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,816.70 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $942.16 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $669.61 | 2019-2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $582.77 | 2019-2025 | Rexulti |
| Lilly USA, LLC | $525.67 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $401.73 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $328.87 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $325.27 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $248.49 | 2019-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $245.18 | 2022-2023 | |
| Exact Sciences Corporation | $244.68 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.21 | 2021-2025 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $211.14 | 2019-2024 | |
| Lundbeck LLC | $197.18 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $175.76 | 2019-2025 | Trelegy Ellipta, Arexvy |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gilhooley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.